Learn from Neal Shore, MD, FACS, a clinician from the ADSTILADRIN clinical trials, about ordering, storage, dosing, preparation, administration, and follow-up appointments.
Dosing
ADSTILADRIN is an intravesical instillation given once every 3 months
ADSTILADRIN administration fits into your existing management of NMIBC
The recommended dose of ADSTILADRIN (nadofaragene firadenovec-vncg) is 75 mL at a concentration of 3 x 1011 viral particles/mL
Instilled once every 3 months into the bladder via a urinary catheter
Premedication with an anticholinergic is recommended before each instillation of
ADSTILADRIN
No reconstitution is needed for ADSTILADRIN.
ADSTILADRIN in practice
Click to play video
Neal Shore,
Neal Shore,
MD, FACS
Related resource
For more on dosing as well as administration details, please see the full Prescribing Information.
DownloadSign Up for Information
Sign up to receive information and updates on ADSTILADRIN
Reference: ADSTILADRIN. Package insert. Ferring Pharmaceuticals, Inc; 2023.
Important Safety Information
INDICATION
ADSTILADRIN is a non-replicating adenoviral vector-based gene therapy indicated for the treatment of adult patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS: ADSTILADRIN is contraindicated in patients with prior hypersensitivity reactions to interferon alfa or to any component of the product.
WARNINGS AND PRECAUTIONS
- Risk with delayed cystectomy: Delaying cystectomy in patients with BCG-unresponsive CIS could lead to development of muscle invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after 3 months or if CIS recurs, consider cystectomy.
- Risk of disseminated adenovirus infection: Persons who are immunocompromised or immunodeficient may be at risk for disseminated infection from ADSTILADRIN due to low levels of replication-competent adenovirus. Avoid ADSTILADRIN exposure to immunocompromised or immunodeficient individuals.
DOSAGE AND ADMINISTRATION: Administer ADSTILADRIN by intravesical instillation only. ADSTILADRIN is not for intravenous use, topical use, or oral administration.
USE IN SPECIFIC POPULATIONS: Advise females of reproductive potential to use effective contraception during ADSTILADRIN treatment and for 6 months after the last dose. Advise male patients with female partners of reproductive potential to use effective contraception during ADSTILADRIN treatment and for 3 months after the last dose.
ADVERSE REACTIONS: The most common (>10%) adverse reactions, including laboratory abnormalities (>15%), were glucose increased, instillation site discharge, triglycerides increased, fatigue, bladder spasm, micturition (urination urgency), creatinine increased, hematuria (blood in urine), phosphate decreased, chills, pyrexia (fever), and dysuria (painful urination).
You are encouraged to report negative side effects of prescription drugs to FDA. Visit www.FDA.gov/medwatch or call 1-800-332-10881-800-332-1088. You may also contact Ferring Pharmaceuticals at 1-888-FERRING1-888-FERRING.
Please see full Prescribing Information for ADSTILADRIN.